Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • Financial Results

    Financial Results - Page 13

    Novartis India Q2 net up 18 percent at Rs 26 crore

    Novartis India Q2 net up 18 percent at Rs 26 crore

    Ruby Khatun Khatun12 Nov 2017 10:30 AM IST
    New Delhi: Drug firm Novartis India reported a 17.60 percent rise in its net profit to Rs 26.12 crore for the quarter ended September 30, 2017.The...
    Dr Lal Path Labs Q2 net profit dips 4 percent at Rs 50.9 crore

    Dr Lal Path Labs Q2 net profit dips 4 percent at Rs 50.9 crore

    Ruby Khatun Khatun12 Nov 2017 10:00 AM IST
    New Delhi: Diagnostic chain Dr. Lal Path Labs reported a 3.96 percent dip in its consolidated net profit to Rs 50.9 crore for the September quarter of...
    Aurobindo Pharma Q2 net up 29 percent at Rs 780.97 crore

    Aurobindo Pharma Q2 net up 29 percent at Rs 780.97 crore

    Ruby Khatun Khatun11 Nov 2017 10:47 AM IST
    New Delhi: Drug firm Aurobindo Pharma reported a 28.96 percent rise in its consolidated net profit to Rs 780.97 crore for the September quarter of the...
    Alkem Labs Q2 Net up 14 percent at Rs 327.44 crore

    Alkem Labs Q2 Net up 14 percent at Rs 327.44 crore

    Ruby Khatun Khatun11 Nov 2017 10:16 AM IST
    New Delhi: Drug firm Alkem Laboratories reported a 13.63 percent rise in consolidated net profit at Rs 327.44 crore for the quarter ended September 30...
    Regeneron third-quarter profit easily tops Street view on Eylea, Dupixent sales

    Regeneron third-quarter profit easily tops Street view on Eylea, Dupixent sales

    Ruby Khatun Khatun11 Nov 2017 9:30 AM IST
    Regeneron Pharmaceuticals Inc on Wednesday reported third-quarter profit that sailed past Wall Street estimates on the strength of increased demand...
    Granules India posts Q2 net profit at Rs 40 crore

    Granules India posts Q2 net profit at Rs 40 crore

    Ruby Khatun Khatun10 Nov 2017 10:47 AM IST
    New Delhi: Pharma company Granules India reported almost flat consolidated net profit at Rs 40.33 crore for the September quarter of the current...
    Alembic Pharma Q2 net rises over 1 percent to Rs 121 crore

    Alembic Pharma Q2 net rises over 1 percent to Rs 121 crore

    Ruby Khatun Khatun9 Nov 2017 10:16 AM IST
    New Delhi: Alembic Pharmaceuticals reported a 1.44 percent increase in consolidated net profit at Rs 121.56 crore for the second quarter ended...
    Cipla shares tank over 7 percent, mcap falls by Rs 3,785.5 crore

    Cipla shares tank over 7 percent, mcap falls by Rs 3,785.5 crore

    Ruby Khatun Khatun8 Nov 2017 10:21 AM IST
    New Delhi: Shares of Cipla slumped over 7 percent even as the company reported a consolidated net profit of Rs 434.95 crore for the second quarter...
    Narayana Hrudayalaya Q2 FY18 Consolidated operating income at Rs 5,592 million

    Narayana Hrudayalaya Q2 FY18 Consolidated operating income at Rs 5,592 million

    Ruby Khatun Khatun8 Nov 2017 10:07 AM IST
    Bengaluru: Narayana Hrudayalaya Limited, a leading healthcare service provider in India, announced its financial results for the second quarter (Q2...
    Strides Shasun Q2 net profit dives 87 percent to Rs 10.73 cr

    Strides Shasun Q2 net profit dives 87 percent to Rs 10.73 cr

    supriya kashyap kashyap2 Nov 2017 12:33 PM IST
    New Delhi: Drug firm Strides Shasun reported an 87.44 percent decline in its consolidated net profit to Rs 10.73 crore for the second quarter ended...
    Pfizer Q3 profit doubles to $2.8 billion, raises full-year revenue forecast

    Pfizer Q3 profit doubles to $2.8 billion, raises full-year revenue forecast

    supriya kashyap kashyap2 Nov 2017 12:33 PM IST
    New York: US pharmaceutical giant Pfizer reported that third-quarter profit more than doubled as strength in newer drugs to treat cancer and other...
    Ajanta Pharma Q2 net grows marginally at Rs 132 cr

    Ajanta Pharma Q2 net grows marginally at Rs 132 cr

    supriya kashyap kashyap1 Nov 2017 11:37 AM IST
    New Delhi: Ajanta Pharma reported a marginal rise in consolidated net profit to Rs 131.89 crore for the second quarter ended September 30, 2017.The...
    PrevNext

    Popular Stories

    Roche begins Phase III clinical trial of Actemra in hospitalised patients with severe COVID-19 pneumonia

    Roche begins Phase III clinical trial of Actemra in hospitalised patients with severe COVID-19...

    Rising prices of hydroxychloroquine raw material forces small scale pharmas in Haridwar to stop production

    Rising prices of hydroxychloroquine raw material forces small scale pharmas in Haridwar to stop...

    Union Pharma Secretary Holds video conference with Pharma manufacturers and associations, takes feedback

    Union Pharma Secretary Holds video conference with Pharma manufacturers and associations, takes...

    Indira IVF to invest Rs 80 crore to expand presence in south India by 2020

    Indira IVF to invest Rs 80 crore to expand presence in south India by 2020

    Lupin Contributes Rs 21 crores in battle against COVID-19

    Lupin Contributes Rs 21 crores in battle against COVID-19

    Cygnus Medicare sells majority stake to Amar Ujala for Rs 130 crore

    Cygnus Medicare sells majority stake to Amar Ujala for Rs 130 crore

    FDA warns about potential cybersecurity vulnerabilities for certain GE Healthcare Clinical Information Central Stations and Telemetry Servers

    FDA warns about potential cybersecurity vulnerabilities for certain GE Healthcare Clinical...

    Bioheaven gets USFDA go ahead to begin phase 2 trial of intranasal vazegepant to treat lung inflammation after COVID-19 infection

    Bioheaven gets USFDA go ahead to begin phase 2 trial of intranasal vazegepant to treat lung...

    View All

    • Email: info@medicaldialogues.in
    • Phone: 011 - 4372 0751

    Website Last Updated On : 13 Oct 2022 5:14 AM GMT
    Company
    • About Us
    • Contact Us
    • Our Team
    • Reach our Editor
    • Feedback
    • Submit Article
    Ads & Legal
    • Advertise
    • Advertise Policy
    • Terms and Conditions
    • Privacy Policy
    • Editorial Policy
    • Comments Policy
    • Disclamier
    Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

    Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

    © 2025 - Medical Dialogues. All Rights Reserved.
    Powered By: Hocalwire
    X
    We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok